Dr. Yang is an analytical development and quality control leader with 20+ years of experience in cell therapy product development. He led analytical development for the first allogeneic T cell product (Ebvallo™) approval by the EMA and supported the FDA BLA filing. Dr. Yang brings more than a decade of analytical experience spanning early-stage development through BLA filing and approval, including extensive work on allogeneic virus-specific T cell products at Atara. He also has deep expertise in analytical strategy and comparability studies to support late-stage development and regulatory submissions.